In an observational study, researchers studied the role of spinal cord and brain atrophy for silent progression and conversion to secondary progressive multiple sclerosis.
Using single molecule array assay, researchers examined sNfL levels of patients with MS who were either on a common diet or ketogenic diet or fasting.
Using MRI rebaselining, researchers sought to assess the efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a prior poor response to disease-modifying therapies.
The researchers sought to determine the clinical and biochemical features of alemtuzumab-induced autoimmune thyroid events and look their risk factors with a focus on fluctuating Graves’ disease.
Researchers sought to determine the dose-response relationship between tolebrutinib, an oral, CNS-penetrant, irreversible inhibitor of Bruton’s tyrosine kinase, and the reduction in new active brain MRI lesions in patients with relapsing MS.
Researchers sought to verify and analyze the relationship between symptoms of depression and attention performance in patients with multiple sclerosis.
Researchers assessed the efficacy and safety of repository corticotropin injection in patients with relapsing-remitting multiple sclerosis relapse with an inadequate response to high-dose corticosteroids.
In this interim analysis, researchers reported the 1-year efficacy and safety data of ocrelizumab in treatment-naïve patients with early-stage relapsing-remitting multiple sclerosis.
Researchers assessed the relationship between lifestyle physical activity and perceived physical and cognitive fatigue in patients with relapsing-remitting multiple sclerosis.
Ublituximab is an investigational glycoengineered anti-CD20 monoclonal antibody.
